Levetiracetam Tablet
Product Images NDC 71335-2282

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71335-2282). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Ectdmodule1usa1)

Chemical structure of Levetiracetam, showing the molecular arrangement with a pyrrolidone ring, an ethyl group, and an amide functional group attached to the central carbon atom.*

FDA Label Image

Fig 1 (Ectdmodule1usa2)

A bar chart comparing the percentage of patients at three treatment levels: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The Y-axis represents the percentage of patients, with values ranging up to approximately 40%. The Placebo group shows about 7.4%, Levetiracetam 1000 mg/day about 37.1%, and Levetiracetam 3000 mg/day about 39.6%.*

FDA Label Image

Fig 2 (Ectdmodule1usa3)

A bar chart comparing the percentage of patients across three groups: placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). The vertical axis shows the percentage of patients.*

FDA Label Image

Fig 3 (Ectdmodule1usa4)

A bar graph comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%. An asterisk is marked above the Levetiracetam bar.*

FDA Label Image

Fig 4 (Ectdmodule1usa5)

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The chart shows approximately 19.6% for the placebo group (N=97) and 44.6% for the Levetiracetam group (N=101), indicating a higher percentage in the Levetiracetam group.*

FDA Label Image

5 (Ectdmodule1usa6)

Bar chart comparing the percentage of patients between two groups: Placebo (N=51) with 19.6% and Levetiracetam (N=58) with 43.1%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Fig 6 (Ectdmodule1usa7)

A bar graph compares the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Placebo group bar shows 45.2%, and the Levetiracetam group bar shows 72.2%, indicating a higher patient percentage for the Levetiracetam group.*

FDA Label Image

Logo (Ectdmodule1usa8)

FDA Label Image

Image (Ectdmodule1usa9)

FDA Label Image

Label (Lbl713352282)

Levetiracetam 500 mg tablets packaging label showing the product name with emphasis on 500 mg strength. The label mentions the package contains 500 tablets. It includes storage instructions, a QR code, barcode, and details about the repackager Bryant Ranch Prepack and manufacturer Torrent Pharmaceuticals Ltd. The label also advises keeping out of reach of children and dispensing in a child-resistant container.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.